The treatment phase of the study was 31 Stopped in December 2009, after a review by the trial Data and Safety Monitoring Board . The DSMB is an independent panel of medical and statistical experts set from the start of the process to regularly check for the occurrence of adverse health events in participants to identify and avoid possible risks from treatment. In December 2009, the board found that 23 of the 106 men testosterone testosterone experienced adverse cardiovascular events associated during the study, of the 103 men who received placebo. The cardiovascular events included myocardial infarction, heart rhythm disturbances and elevated blood pressure, and one death from a suspected heart attack.

‘courtesy of you, the entire Kaiser Daily Health Policy view Report, search the archives, or sign up be published for e-mail notification on Kaiser Daily Health Policy Report strongly supports kaiser network. A free service of The Henry J. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.– cooperation among governments and stakeholders, like group healthcare professionals and people with diabetes new legislative new legislation or improve implementation of the existing legislation to combat the diabetes epidemic;.

Other articles from category "hepatology":

Random articles